Document is current

Article History

Received: 21 August 2019

Accepted: 3 February 2020

First Online: 26 February 2020

Competing interests

: All co-authors except Dr. Krystal declare no completing interests. The following competing interests for John H. Krystal: RE: John H. Krystal, MD 2019 Financial Disclosure.ConsultantNote: – The Individual Consultant Agreements listed below are less than $10,000 per yearAstraZeneca PharmaceuticalsBiogen, Idec, MABiomedisyn CorporationBionomics, Limited (Australia)Boehringer Ingelheim InternationalConcert Pharmaceuticals, Inc.Epiodyne, Inc.Heptares Therapeutics, Limited (UK)Janssen Research & DevelopmentL.E.K. ConsultingOtsuka America Pharmaceutical, Inc.Perception Neuroscience Holdings, Inc.Spring Care, Inc.Sunovion Pharmaceuticals, Inc.Takeda IndustriesTaisho Pharmaceutical Co., Ltd<u>Scientific Advisory Board</u>Bioasis Technologies, Inc.Biohaven PharmaceuticalsBioXcel Therapeutics, Inc. (Clinical Advisory Board)Cadent Therapeutics (Clinical Advisory Board)PsychoGenics, Inc.Stanley Center for Psychiatric research at the Broad Institute of MIT and HarvardLohocla Research Corporation<u>Stock</u>ArRETT Neuroscience, Inc.Biohaven PharmaceuticalsSage PharmaceuticalsSpring Care, Inc.<u>Stock Options</u>Biohaven Pharmaceuticals Medical SciencesBlackThorn Therapeutics, Inc.Storm Biosciences, Inc.<u>Income Greater than $10,000</u><u>Editorial Board</u>Editor - Biological Psychiatry<u>Patents and Inventions</u>1) Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US Patent #:5,447,948.September 5, 19952) Vladimir, Coric, Krystal, John H, Sanacora, Gerard – Glutamate Modulating Agents in the Treatment of Mental Disorders US Patent No. 8,778,979 B2 Patent Issue Date: July 15, 2014. US Patent Application No. 15/695,164: Filing Date: 09/05/20173) Charney D, Krystal JH, Manji H, Matthew S, Zarate C., - Intranasal Administration of Ketamine to Treat Depression United States Application No. 14/197,767 filed on March 5, 2014; United States application or Patent Cooperation Treaty (PCT) International application No. 14/306,382 filed on June 17, 20144) Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, Krystal, JH, Department of Veterans Affairs “Methods for Treating Suicidal Ideation”, Patent Application No. 14/197.767 filed on March 5, 2014 by Yale University Office of Cooperative Research5) Arias A, Petrakis I, Krystal JH. – Composition and methods to treat addiction.Provisional Use Patent Application no.61/973/961. April 2, 2014. Filed by Yale University Office of Cooperative Research.6) Chekroud, A., Gueorguieva, R., & Krystal, JH. “Treatment Selection for Major Depressive Disorder” [filing date 3rd June 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission by Yale University7) Gihyun, Yoon, Petrakis I, Krystal JH – Compounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases. U. S. Provisional Patent Application No. 62/444,552, filed on January10, 2017 by Yale University Office of Cooperative Research OCR 7088 US018) Abdallah, C, Krystal, JH, Duman, R, Sanacora, G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. U.S. Provisional Patent Application No. 047162-7177P1 (00754) filed on August 20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01<u>NON-Federal Research Support</u>AstraZeneca Pharmaceuticals provides the drug, Saracatinib, for research related to NIAAA grant “Center for Translational Neuroscience of Alcoholism [CTNA-4].